Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes

Summary

Viking Therapeutics announced pricing of a concurrent $500 million offering of common stock and convertible senior notes. The offering was upsized and represents a significant capital raise for the clinical-stage biopharmaceutical company.